ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
India’s patent office has ruled that Gilead Sciences’ hepatitis C drug Sovaldi is not sufficiently innovative to warrant patent protection in India. According to the agency, the drug’s active ingredient, sofosbuvir, is simply a previously known molecule in which the orientation of the fluoro group has been modified to reduce toxicity. Last September, Gilead agreed to license rights to Sovaldi to several Indian generic drug firms for modest royalties, provided they sell it only in developing countries. India’s Initiative for Medicines, Access & Knowledge says it expects the ruling to open the playing field and lead to even lower prices for sofosbuvir.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X